This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 25 February - 2 March 2024, and includes updates on on cholera, avian influenza, SARS-CoV-2 variant classification, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 11-17 February 2024, and includes updates on SARS-CoV-2 variant classification, diphtheria, chikungunya, dengue, influenza A(H5N1), a human case of co-infection with seasonal influenza A(H3N2) and avian influenza A(H10N5), Middle East respiratory syndrome coronavirus (MERS-CoV), and an overview of respiratory virus epidemiology in the EU/EEA.
Since the beginning of 2023, and as of 16 February 2024, six MERS-CoV cases, including two fatalities, have been reported with the date of onset in 2023 by Saudi Arabia (5) and the United Arab Emirates (1).
Since the beginning of 2023, and as of 16 February 2024, six MERS-CoV cases, including two fatalities, have been reported with the date of onset in 2023 by Saudi Arabia (5) and the United Arab Emirates (1).
Since the beginning of 2023, and as of 16 February 2024, six MERS-CoV cases, including two fatalities, have been reported with the date of onset in 2023 by Saudi Arabia (5) and the United Arab Emirates (1).
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.